Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 4/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8930440 | 0.88 | OPRD1 (0.49) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 | |
| SCHEMBL4575665 | 0.88 | OPRD1 (0.49) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 | |
| SCHEMBL4575510 | 0.88 | OPRD1 (0.49) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 | |
| SCHEMBL4577095 | 0.88 | OPRD1 (0.51) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 | |
| SCHEMBL4576003 | 0.88 | OPRD1 (0.43) | OPRD1OPRM1CYP3A4CYP1A2MEN1 | |
| SCHEMBL4585750 | 0.86 | OPRD1 (0.64) | OPRD1OPRM1CYP3A4CYP1A2MEN1 | |
| SCHEMBL5300451 | 0.85 | OPRD1 (0.72) | OPRD1OPRM1CYP3A4CYP1A2MEN1 | |
| SCHEMBL4586928 | 0.82 | OPRD1 (0.77) | OPRD1OPRM1CYP3A4CYP1A2MEN1 | |
| SCHEMBL29967893 | 0.82 | OPRD1 (0.77) | OPRD1OPRM1CYP3A4CYP1A2MEN1 | |
| SCHEMBL4575785 | 0.80 | CYP3A4 (0.58) | OPRD1OPRM1CYP3A4CYP1A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285569-B2 | Tricycles, their manufacture and use as pharmaceutical agents | HOFF HOFFMANN-LA ROCHE INC. (US) | 2007-10-23 | — | — | US | claimed |
| US-20060069145-A1 | Tricycles, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-03-30 | — | — | US | claimed |
| EP-1450807-A4 | METHOD OF TREATING DEPRESSION WITH DELTA RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS INC (US) | 2008-06-25 | — | — | EP | disclosed |
| US-7285569-B2 | Tricycles, their manufacture and use as pharmaceutical agents | HOFF HOFFMANN-LA ROCHE INC. (US) | 2007-10-23 | — | — | US | disclosed |
| WO-2007027987-A2 | METHOD OF TREATING PARKINSON'S DISEASE WITH DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA RECEPTOR AGONIST ACTIVITY | MOUNT COOK BIOSCIENCES, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| US-7030124-B2 | Method of treating depression with delta receptor agonist compounds | ARDENT PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-20060069145-A1 | Tricycles, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-03-30 | — | — | US | disclosed |
| EP-1450807-A1 | METHOD OF TREATING DEPRESSION WITH DELTA RECEPTOR AGONIST COMPOUNDS | Ardent Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20030144299-A1 | Method of treating depression with delta receptor agonist compounds | DMK PHARMACEUTICALS CORPORATION | 2003-07-31 | — | — | US | disclosed |
| WO-2003037342-A1 | METHOD OF TREATING DEPRESSION WITH DELTA RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144299-A1 | Method of treating depression with delta receptor agonist compounds | CHRND, CHRNE, CHRNA3 | OPRD1 9/4885OPRM1 110/4885CYP3A4 3126/4885 |
| US-20060069145-A1 | Tricycles, their manufacture and use as pharmaceutical agents | ABCB1, CYP3A43, CYP3A5 | OPRD1 1298/4885OPRM1 1269/4885CYP3A4 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.